
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

Top-line results are expected in the second quarter of 2017The randomized, double-blind, placebo-controlled Phase III study ...

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a ...
Click to continue to site. Closing